RE:RE:Funny, Guess they allow dogs in the office?I need to update the list of hints.
jfm1330 wrote: Nothing really new about oncology, but Levesque high enthusiasm is still there. That is very good to see at this point knowing that they are at twice the MTD of docetaxel alone. He even sais that they could publish the results of phase Ia at the beginning of 2022 because the trial may last longer than expected. He also alluded to the possibility of not reaching the MTD in this trial. He also said that he does not want to report anything anecdotal on efficacy, so he wants validated data. The other interesting nugget is that every patient enrolled is tested for sortilin expression. So when they enroll a patient not expressing sortilin on its cancer cells, they know it. That means that they can compare the pharmacokinetics of patients with and without sortilin. So this could give them early indication that the PDC is internalized in sortilin expressing patients and only in healthy tissue in patient not expressing sortilin on their cancer cells. To me it is clear that he is maintaining this high enthusiasm because what they saw up to now is very good. Otherwise it would be pure hypocrisy on his part and it's not his style. I also liked what he said about a NASH partnership. He seems to truly believe that something good will be done on that front.